See more : AYO Technology Solutions Limited (AYO.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Astria Therapeutics, Inc. (ATXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Astria Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Halma plc (HALMY) Income Statement Analysis – Financial Results
- Advanced Blockchain AG (BWQ.DE) Income Statement Analysis – Financial Results
- BLIS Technologies Limited (BLT.NZ) Income Statement Analysis – Financial Results
- Sierra Metals Inc. (SMTS) Income Statement Analysis – Financial Results
- Lowell Farms Inc. (LOWL.CN) Income Statement Analysis – Financial Results
Astria Therapeutics, Inc. (ATXS)
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 26.00K | 119.00K | 0.00 | 395.00K | 202.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -26.00K | -119.00K | 500.00K | -395.00K | -202.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 57.33M | 34.26M | 15.55M | 25.59M | 18.32M | 17.04M | 18.68M | 25.45M | 23.03M | 15.69M | 13.99M | 12.41K |
| General & Administrative | 25.70M | 19.24M | 14.81M | 11.85M | 8.77M | 9.33M | 8.91M | 10.11M | 8.63M | 6.00M | 4.13M | 3.27K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 718.00 |
| SG&A | 25.70M | 19.24M | 14.81M | 11.85M | 8.77M | 9.33M | 8.91M | 10.11M | 8.63M | 6.00M | 4.13M | 3.98K |
| Other Expenses | 0.00 | -55.00K | -58.00K | -101.00K | -50.00K | 176.00K | 32.00K | 93.00K | 7.00K | 3.00K | 1.00K | 0.00 |
| Operating Expenses | 83.03M | 53.50M | 30.36M | 37.44M | 27.09M | 26.37M | 27.59M | 35.56M | 31.66M | 21.68M | 18.12M | 15.67K |
| Cost & Expenses | 83.03M | 53.50M | 30.36M | 37.44M | 27.09M | 26.37M | 27.59M | 35.56M | 31.66M | 21.68M | 18.12M | 15.67K |
| Interest Income | 10.20M | 1.72M | 122.00K | 236.00K | 845.00K | 425.00K | 160.00K | 242.00K | 0.00 | 0.00 | 0.00 | 4.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 462.00K | 837.00K | 978.00K | 206.00K | 0.00 | 0.00 |
| Depreciation & Amortization | -15.20M | 228.49K | -164.62M | 26.00K | 26.00K | 119.00K | 304.00K | 395.00K | 202.00K | 248.00K | 320.00K | 327.00 |
| EBITDA | -83.03M | -53.50M | -194.98M | -37.44M | -26.27M | -25.65M | -26.60M | -34.83M | -31.46M | -21.43M | -17.80M | -15.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,319.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.03M | -53.50M | -194.98M | -37.44M | -27.09M | -26.37M | -27.09M | -35.56M | -31.66M | -21.68M | -18.12M | -15.67K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,418.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.14M | 1.67M | 64.00K | 135.00K | 795.00K | 501.00K | -270.00K | -502.00K | -971.00K | -203.00K | 1.00K | 4.00 |
| Income Before Tax | -72.89M | -51.83M | -194.91M | -37.30M | -26.29M | -25.87M | -27.36M | -36.06M | -32.63M | -21.88M | -18.12M | -15.67K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,472.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.67M | -164.74M | -236.00K | -50.00K | 601.00K | 494.00K | 930.00K | 783.00K | 209.00K | 0.00 | 0.00 |
| Net Income | -72.89M | -50.17M | -30.17M | -37.06M | -26.24M | -25.87M | -27.36M | -36.06M | -32.63M | -21.88M | -18.12M | -15.67K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,472.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.11 |
| EPS Diluted | -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.11 |
| Weighted Avg Shares Out | 30.12M | 14.62M | 8.93M | 3.06M | 1.87M | 842.47K | 361.36K | 270.50K | 134.03K | 144.42K | 144.42K | 144.42K |
| Weighted Avg Shares Out (Dil) | 30.12M | 14.62M | 8.93M | 3.06M | 1.87M | 842.47K | 361.36K | 270.50K | 134.03K | 144.42K | 144.42K | 144.42K |
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and information on STAR-0215 and STAR-0310 at...
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 36,800 shares of Astria's common stock on November 1, 2023 under Astria's 2022 Inducement Stock Incentive Plan....
Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D.,...
Astria Therapeutics strikes exclusive license agreement for dermatitis treatment portfolio
Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases. The focus of the collaboration centers on the development of...
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the pricing of an underwritten offering of (i) 8,253,895 shares of...
Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 61,000 shares of Astria's common stock...
Astria Therapeutics: Too Much Baggage, Too Strong A Competition
Astria Therapeutics (formerly Catabasis Pharma) has raised $100 million and acquired Quellis to develop STAR-0215, a plasma kallikrein inhibitor for hereditary angioedema (HAE). STAR-0215 has a longer half-life than existing HAE treatments, potentially offering a longer duration of action. The...
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that preclinical data supporting STAR-0215's profile as a...
Source: https://incomestatements.info
Category: Stock Reports